In patients with severe community acquired pneumonia (CAP) does the use of hydrocortisone compared to a placebo reduce 28-day mortality?Continue reading »
In patients with severe COVID, does 12mg dexamethasone vs 6mg dexamethasone increase the number of days alive without life support at 28 days?Continue reading »
In patients with severe COVID-19, does intravenous hydrocortisone (either as a fixed dose or restricted to when shock is clinically evident) compared with standard care, improve 21-day organ support free days?Continue reading »
In hospitalised patients with SARS-CoV-2 infection does dexamethasone in additional to usual care, compared to usual care alone, reduce 28-day mortality?Continue reading »
In critically ill patients with septic shock, does the combination of hydrocortisone plus fludrocortisone therapy reduce 90 day mortality?Continue reading »
In critically ill patients with septic shock, does hydrocortisone compared with placebo, reduce 90 day mortality?Continue reading »
In patients with septic shock, do corticosteroids compared to placebo reduce mortality?
This is an editorial blog post in anticipation of the ADRENAL trial results to be presented at #CCR18.
In patients with septic shock who are treated with corticosteroids, does tight glycaemic control (4.44–6.1 mmol/l) compared with less-tight glycaemic control (<8.3 mmol/l) reduce in-hospital mortality?Continue reading »
Does intravenous vitamin C, hydrocortisone and thiamine in addition to standard treatment, improve mortality in ICU patients with severe sepsis or septic shock, compared with standard treatment alone?Continue reading »
In patients with severe sepsis does hydrocortisone compared to placebo prevent the development of septic shock?Continue reading »